In the coming years, several products (vaccines, monoclonal antibodies, antivirals) for prevention and/or treatment of RSV in different age groups will be developed and become available for use. However, there are no universally agreed study designs or endpoints to measure RSV product effectiveness. Developing scientific consensus on appropriate study designs helps provide relevant information to those in charge of public health programmes as well as manufacturers and regulators once the products become available. PROMISE is leveraging the experience from other European projects, especially I-MOVE and DRIVE that focus on influenza.
Our work plan focuses on: